Navigation Links
Polaris Group Files New IND for ADI-PEG 20 in Leukemia
Date:12/2/2013

SAN DIEGO, Dec. 2, 2013 /PRNewswire/ -- Polaris Group announced today that it has filed an Investigational New Drug Application (IND) application with the United States Food and Drug Administration (FDA) to begin Phase 1 clinical trials to test ADI-PEG 20, arginine deiminase formulated with polyethylene glycol, for the treatment of acute myeloid leukemia. The FDA has reviewed this application, waived the 30-day review period and allowed treatment to begin. Polaris Group has previously filed other INDs under which it is conducting clinical trials on ADI-PEG 20 for the treatment of multiple other indications, including metastatic melanoma, prostate cancer, and hepatocellular carcinoma. The latter indication is already in a global Phase 3 study.

"This is another IND that expands the portfolio of indications for which ADI-PEG 20 is under development to hematologic malignancies," said John Bomalaski, M.D., Executive Vice President of Medical Affairs at Polaris Group. "Studies in leukemia and lymphoma will expand the studies currently underway with ADI-PEG 20, in addition to the solid tumors already under study. ADI-PEG 20 has a novel mechanism of action and well documented tolerability that we believe makes ADI-PEG 20 an ideal candidate both as monotherapy and to combine with other agents, including cytotoxics."

About ADI-PEG 20

ADI-PEG 20 is a biologic being developed by Polaris Group to treat cancers, especially those carrying a major metabolic defect that renders such cancer cells, unlike normal cells, unable to internally synthesize arginine. Because arginine is one of the 20 amino acids that are essential for protein synthesis and survival of cells, it is believed these cancer cells become dependent upon the external supply of arginine to survive and grow. ADI-PEG 20 is designed to systemically deplete the external supply of arginine, which causes arginine-dependent cancer cells to die while leaving the normal cells unharmed. Multiple cancers have been reported to have a high degree of arginine-dependency.

About Polaris Group

Polaris Group is a privately held biopharmaceutical company that specializes in the research and development of protein drugs to treat cancer and other debilitating diseases. The company's lead therapeutic, ADI-PEG 20, is currently being evaluated in a pivotal Phase 3 trial for hepatocellular carcinoma. Polaris Group is also investigating ADI-PEG 20 as a treatment for other cancers. In addition to the ADI-PEG 20 program, Polaris Group is researching and developing other biotherapeutic agents and is advancing a small molecule drug program that utilizes a rational structure-based approach to design novel compounds that inhibit the biological function of cancer-related protein targets.

For additional information please visit www.polarispharma.com


'/>"/>
SOURCE Polaris Group
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Polaris Group Announces Treatment of First Patient in Phase 2 Study of ADI-PEG 20 in Acute Myeloid Leukemia
2. Polaris Group Lead Therapeutic Candidate ADI-PEG 20 Demonstrates Potential Anticancer Activity in Various Metastatic Sarcomas and Bladder Cancers That Are Deficient in Key Metabolic Protein, and Enhanced Effects with Combination Therapy in Melanoma
3. Millennium HealthCare Inc. Installs VasoScan Cardiovascular Assessment Test in Select Physician Groups during First Week of Launch
4. The Huntzinger Management Group, Inc. (HMG) Reporting Significant Growth and Business Expansion in 2013
5. Jean Coutu Group chooses Microsoft Dynamics for Retail to streamline operations
6. Life Care Solutions Group: The #Vaginal Mesh Debacle Is More Complicated Then The Hip Settlement
7. Implantable Medical Device Group formed to Reduce Risk and Simplify Management of Active Implant Projects
8. Simcere Pharmaceutical Group Announces Extraordinary General Meeting of Shareholders
9. HyGreen, Inc. Signs Distribution Agreement with Unison Group
10. Simcere Pharmaceutical Group Reports Preliminary Unaudited Third Quarter 2013 Results
11. Triangle Insights Group Opens RTP Office
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... , February 10, 2016 --> --> ... Japan .  --> Japan .  --> A ... With submission, Shire continues to strengthen ... With submission, Shire continues to strengthen its presence ... submission, Shire continues to strengthen its presence ...
(Date:2/10/2016)... SEATTLE , Feb. 10, 2016  Resolve ... potentially transformative new approaches to the treatment of ... completion of a multiple ascending dose study in ... lead compound RSLV-132. --> ... double-blind, placebo-controlled multiple ascending dose study of RSLV-132 ...
(Date:2/10/2016)... YORK , Feb. 10, 2016 Immune ... biopharmaceutical company, announced today that it has filed a ... Leukemia and other cancers. --> ... treating cancer by administration of Ceplene (histamine dihydrochloride) in ... provides methods of predicting the efficacy of Ceplene and ...
Breaking Medicine Technology:
(Date:2/10/2016)... ... February 10, 2016 , ... ... S.S. Nesbitt as the latest addition to its growing list of Partner Firms. ... throughout the Southeast, from Orlando to Huntsville and in between. , Harnessing the ...
(Date:2/10/2016)... ... , ... AHRA: The Association for Medical Imaging Management announced ... serve as keynote speaker at the organization’s 2016 Spring Conference. Fox’s topic, Lead ... communicate with their own organizational staff and leadership. , “I am so ...
(Date:2/10/2016)... Florida (PRWEB) , ... February 10, 2016 , ... ... Club) announced that it has been awarded the prestigious Distinguished Emerald Club of ... award program conducted by BoardRoom magazine, one of the most respected trade publications ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... Workrite Ergonomics ... most versatile series of monitor mounts ever. , “Our goal was to develop ... easy to install system that we have ever created.” said Darren Hulsey, Product Manager ...
(Date:2/10/2016)... ... ... A new leadership team for Mid-South Youth Camp, operated by Freed-Hardeman University, ... Monday night, Feb. 8, prior to the evening session of the university’s 80th Annual ... GO! Camp, has been named director. Gayle McDonald, currently the assistant director of MSYC, ...
Breaking Medicine News(10 mins):